NeoGenomics Inc (NEO)

Operating profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Operating income (ttm) US$ in thousands -107,736 -115,545 -130,860 -140,668 -157,623 -172,807 -173,010 -155,675 -118,754 -71,648 -27,266 -23,806 -13,992 -17,210 -18,220 5,165 13,006 13,506 13,767 10,083
Revenue (ttm) US$ in thousands 601,638 580,487 554,336 529,041 507,523 493,983 486,680 484,258 482,622 482,400 486,504 451,757 442,254 425,319 404,547 419,283 408,830 378,437 342,861 308,894
Operating profit margin -17.91% -19.90% -23.61% -26.59% -31.06% -34.98% -35.55% -32.15% -24.61% -14.85% -5.60% -5.27% -3.16% -4.05% -4.50% 1.23% 3.18% 3.57% 4.02% 3.26%

December 31, 2023 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $-107,736K ÷ $601,638K
= -17.91%

Neogenomics Inc.'s operating profit margin has shown a declining trend over the past eight quarters. The company's operating profit margin was in negative territory throughout the period, indicating that its operating expenses exceeded its operating income.

In Q4 2023, the operating profit margin improved slightly compared to the previous quarter but remained in negative territory at -16.34%. While this improvement is a positive sign, the company still needs to enhance its operational efficiency to generate more profits from its core business activities.

It is worth noting that Neogenomics Inc.'s operating profit margin has been consistently negative, which raises concerns about its ability to control costs and generate sustainable profitability. Further analysis of the company's cost structure, revenue streams, and operational processes is necessary to identify areas for improvement and enhance its overall financial performance.